NDC 72572-585-01 - Propofol
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 72572-585
- Requested NDC
- 72572-585-01
- Package NDCs from labels
- 72572-585-01, 72572-585-10
- Manufacturer
- Civica, Inc. | Hikma Pharmaceuticals USA Inc.
- Effective date
- 2021-02-23
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| PROPOFOL INJECTABLE EMULSION, USP | Civica, Inc. | Hikma Pharmaceuticals USA Inc. | 2021-02-23 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 72572-585-01 | ML - Milliliter | 72572-585 | 3abcd0e9-7341-4b46-9efe-dc582b1b5f22 | 1 | 2021-03-02 |
| 72572-585-10 | ML - Milliliter | 72572-585 | e2798f85-c08b-498e-820e-56ece7fa31e8 | 1 | 2021-03-02 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Propofol | PROPOFOL | Civica, Inc | 9ba70032-40c2-41c5-9f99-d1f94032d3dc | 2026-09-18 | Warnings, Adverse reactions | YI7VU623SF |
| PROPOFOL | PROPOFOL | Hospira, Inc. | 28d7ba00-f824-4e55-139a-03f509c099db | 2026-08-13 | Warnings, Adverse reactions | YI7VU623SF |
| propofol | PROPOFOL | Meitheal Pharmaceuticals Inc. | 548d5192-2e5e-4c1b-8f17-940b6e791ae5 | 2025-12-12 | Warnings, Adverse reactions | YI7VU623SF |
| Diprivan | PROPOFOL | Fresenius Kabi USA, LLC | e3105799-a4b6-f3f4-e6e2-b2b29bbdb538 | 2025-09-11 | Warnings, Adverse reactions | YI7VU623SF |
| Diprivan | PROPOFOL | Fresenius Kabi USA, LLC | fee3bd4a-ade3-41fa-839a-48e9af69bcf4 | 2025-09-10 | Warnings, Adverse reactions | YI7VU623SF |
| propofol | PROPOFOL | Sagent Pharmaceuticals | fa93f173-7858-4d88-860e-76ab97e65c2f | 2025-06-07 | Warnings, Adverse reactions | YI7VU623SF |
| PROPOFOL | PROPOFOL | Amneal Pharmaceuticals Private Limited | 6833edd6-ba8a-4b97-a872-ab253c64a903 | 2025-05-20 | Warnings, Adverse reactions | YI7VU623SF |
| Propofol | PROPOFOL | Avenacy, LLC | de351d5f-581d-4768-a4af-fbd8e5bce264 | 2025-04-30 | Warnings, Adverse reactions | YI7VU623SF |
| Diprivan | PROPOFOL | Fresenius Kabi USA, LLC | d1ae9e26-ffd6-43df-bbd6-869cdede6afe | 2025-04-21 | Warnings, Adverse reactions | YI7VU623SF |
| Diprivan | PROPOFOL | Fresenius Kabi USA, LLC | ee0c3437-614d-4631-a061-257f5f60c70b | 2025-02-20 | Warnings, Adverse reactions | YI7VU623SF |
| PROPOFOL | PROPOFOL | HF Acquisition Co LLC, DBA HealthFirst | 99af9e0a-c268-84ca-e053-2a95a90a0a3e | 2025-01-08 | Warnings, Adverse reactions | YI7VU623SF |
| PROPOFOL | PROPOFOL | HF Acquisition Co LLC, DBA HealthFirst | 99c8438a-2b3c-796e-e053-2a95a90a0200 | 2025-01-08 | Warnings, Adverse reactions | YI7VU623SF |
| Diprivan | PROPOFOL | Fresenius Kabi USA, LLC | 5cec3b97-5183-4a9d-accd-21e76c99d3dd | 2024-04-18 | Warnings, Adverse reactions | YI7VU623SF |
| 2ec1f330-c8bc-4c28-b31e-6771177f7c43 | 639e5842-a77e-4e73-8d2c-94caa102ca59 | 2023-01-04 | Warnings, Adverse reactions | 639e5842-a77e-4e73-8d2c-94caa102ca59 | ||
| PROPOFOL | PROPOFOL | HF Acquisition Co LLC, DBA HealthFirst | 7b9599e0-5bad-742d-e053-2991aa0aee97 | 2022-12-09 | Warnings, Adverse reactions | YI7VU623SF |
| PROPOFOL | PROPOFOL | Hikma Pharmaceuticals USA Inc. | fdb77e13-f5a7-4c4a-9f8e-338b702239c8 | 2022-11-18 | Warnings, Adverse reactions | ANDA074848 YI7VU623SF |
| Propofol Injectable Emulsion | PROPOFOL INJECTABLE EMULSION | Dr. Reddy's Laboratories, Inc. | 800646b8-83a8-01d9-3dc8-bb2ddcb8570c | 2022-09-30 | Warnings, Adverse reactions | YI7VU623SF |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.